^
    Back
    Association details:
    Biomarker:HER-2 overexpression
    Cancer:Endometrial Adenocarcinoma
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Gastric Cancer)
    New
    Excerpt:
    Herceptin should only be used in patients with metastatic gastric cancer whose tumours have HER2 overexpression...
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu

    Published date:
    07/10/2018
    Excerpt:
    ...phase II trial compared carboplatin-paclitaxel with and without trastuzumab in patients with advanced or recurrent uterine serous carcinoma who overexpress HER2/neu....median progression-free survival was 8.0 months (control) versus 12.6 months (experimental; P = .005; hazard ratio [HR], 0.44; 90% CI, 0.26 to 0.76)...Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival.
    Secondary therapy:
    carboplatin + paclitaxel
    DOI:
    10.1200/JCO.2017.76.5966
    Trial ID:
    NCT01367002